FDA de­lays re­view of Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter da­ta up­date

The FDA has ex­tend­ed its re­view of Bio­Marin’s gene ther­a­py for he­mo­phil­ia A by three months, for­mal­iz­ing an ex­pect­ed de­lay that will now push out a de­ci­sion to the end of June.

Bio­Marin told in­vestors in No­vem­ber, af­ter sub­mit­ting three-year da­ta analy­sis from a Phase III tri­al, that the FDA said it may con­sti­tute a ma­jor amend­ment that war­rants ex­tra time for re­view.

And that’s ex­act­ly what hap­pened, with the agency cit­ing “sub­stan­tial amount of ad­di­tion­al da­ta,”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER